Isis Books Kynamro Milestone; Seeks Partners For Other Pipeline Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
The focus at Isis turns to the near-term prospects of an approval for the cholesterol drug Kynamro and to business development.
You may also be interested in...
Sanofi/Genzyme And Isis Submit Kynamro For Lowering Cholesterol
It’s been a long haul, but Sanofi’s Genzyme business unit and Isis have submitted their NDA for a drug that helps lower cholesterol levels in high-risk patients with a rare genetic cardiovascular disease that doesn’t respond well to statins.
Biogen Strikes A Deal With Isis For Antisense Technology
Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.